Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretic testing in chronic kidney disease
NL-OMON57356Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of bumetanide and hydrochlorothiazide in chronic kidney disease (CKD) (3 arms), sponsored by Erasmus MC. Primary endpoint: Composite outcome of CKD progression. Started Apr 2025; status: recruiting.
02
Drugs
bumetanidehydrochlorothiazide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON57356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57356.